Tiziana Life Sciences Ltd (TLSA) stock
Close on Nov 12, 2026Market cap $73.57MP/E –Yield –
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Dec 31, 2025
Valuation
- Market cap
- $73.57M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- -17.49%
Fundamentals
- EPS, diluted
- -$0.16
- Free cash flow
- -$12.87M
Trading
- Previous close
- $0.62
- Open
- $0.63
- Day's range
- $0.61 – $0.65
- Volume
- 194,476
- Average volume (20 days)
- 541,569
- Beta (5 years)
- -0.05
- 52-week range
- $0.57 – $1.90
- RSI (14 days)
- 31.2
- Volatility (1 year)
- 85.3%
- Relative volume
- 0.53×
- WACC
- 7.4%
Market cap history
Month-end market cap since 2018, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 12, 2026. The S&P 500 is measured by the SPY fund.
| Period | TLSA | S&P 500 | Difference | TLSA per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -44.0% | -2.7% | −41.3 pts | ||
| 3 months | -38.3% | -1.7% | −36.6 pts | ||
| Year to date | -59.0% | +11.9% | −70.9 pts | ||
| 1 year | -65.7% | +12.0% | −77.7 pts | ||
| 3 years | +3.5% | +78.2% | −74.7 pts | +1.1% | +21.2% |
| 5 years | -56.1% | +73.2% | −129.3 pts | -15.2% | +11.6% |
Eleven years at a glance
Fiscal years 2015 to 2025, USD
Operating income
EPS, diluted
Free cash flow
Press releases
Releases Tiziana Life Sciences filed with the SEC as exhibits to Form 8-K or 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
About Tiziana Life Sciences
Pharmaceutical Preparations
Tiziana Life Sciences Ltd is a clinical-stage biotechnology company focused on developing therapies for oncology and immune-mediated diseases with high unmet medical need. The company concentrates on developing novel drug candidates, primarily monoclonal antibodies targeting immune pathways. Its lead product candidate is Foralumab, which is being investigated across various indications including non-active secondary progressive multiple sclerosis, Alzheimer's disease, amyotrophic lateral sclerosis, and multiple system atrophy. Additionally, its pipeline includes TZLS-501, an anti-IL6R monoclonal antibody. The company aims to provide treatments for patient populations suffering from neurodegenerative and inflammatory conditions.
Company profile, executives and historyTiziana Life Sciences stock: common questions
What is Tiziana Life Sciences's stock price?
TLSA closed at $0.61 on Nov 12, 2026, down 1.69% on the day. Over the past 52 weeks it traded between $0.57 and $1.90.
What is Tiziana Life Sciences's market cap?
Tiziana Life Sciences was worth $73.57M at the close on Nov 12, 2026: the share price times the diluted shares outstanding.
What is TLSA's P/E ratio?
Tiziana Life Sciences lost money over fiscal 2025 (diluted EPS -$0.16), so it has no meaningful P/E ratio.
Does Tiziana Life Sciences pay a dividend?
No. Tiziana Life Sciences has not paid a cash dividend over the last twelve months.
How has TLSA stock performed over the past year?
Including dividends, TLSA returned -65.7% over the past year, against +12.0% for the S&P 500.
How many TLSA shares are sold short?
3M shares were sold short at the latest FINRA report, 13.66% of the float, or 7.0 days of average trading volume.
Who are Tiziana Life Sciences's competitors?
Companies most similar to Tiziana Life Sciences by business, industry and size include TGTX, ZBIO, CLYM, BDRX, QNTM.
See a number that looks wrong?